Valeant goes on defense; Isis pockets $5M in GSK deal;

@FierceBiotech: ICYMI: AstraZeneca's gout drug wins faint praise from FDA advisers. Article | Follow @FierceBiotech

@JohnCFierce: ICYMI: Alexion wins priority review voucher with FDA OK of Strensiq. Report | Follow @JohnCFierce

@DamianFierce: This is an excellently reported /Philidor story that deserves a more alluring headline. Perhaps "One Weird Trick To Boost Drug Revenue," and then they could do like a quiz to "Find Your Philidor Alter-Ego" WSJ story | Follow @DamianFierce

> Valeant Pharmaceuticals ($VRX), facing mounting scrutiny over its accounting practices and business model, has formed a committee to review its reliance on specialty pharmacies and called on the SEC to investigate the short sellers lobbing accusations. Story

> Irish biotech Nuritas raised $3.2 million in seed financing to develop products that straddle the divide between nutrition and therapeutics. More

> Isis Pharmaceuticals ($ISIS) pocketed $5 million from its ongoing collaboration with GlaxoSmithKline ($GSK) after kicking off a Phase I study on a treatment for ocular disorders. News

Medical Device News

@FierceMedDev: Check out this year's Fierce 15: The new strategic med tech mania sets the stage for 2015's Fierce 15. Feature | Follow @FierceMedDev

@EmilyWFierce: ICYMI Friday: Kadcyla's miss in stomach cancer dents Roche's effort to reap more from new drugs. FiercePharma story | Follow @EmilyWFierce

> Healthcare, wellness drive Philips growth as it works to shed lighting, maintain cautious M&A strategy. Story

> Report: Buyer interest heating up for Swiss Dx company Unilabs. More

> Walgreens freezes partnership with Theranos amid testing fallout. Report

Pharma News

@FiercePharma: ICYMI from FiercePharmaAsia: Ranbaxy merger showing sharp cons as well as pros for Sun Pharma. Item | Follow @FiercePharma

@EricPFierce: ICYMI from FiercePharmaManufacturing: Japan's says its mAb work with means a need for a $309M API plant expansion. Article | Follow @EricPFierce

@CarlyHFierce: SOMEbody got burned out on grammar by slide 82 of the $VRX presentation. "Why does R&O and Philidor have the same phone number?" | Follow @CarlyHFierce

> Merck discounts Remicade in U.K. as it tries to fend off biosimilars. Report

> Defensive Valeant sets up board committee to probe fraud allegations. Story

> U.K.'s Big Kahuna investor spurs GlaxoSmithKline toward a Big Split. Article

Animal Health News

> Subway ups the ante on antibiotic-free meat pledge. More

> Lilly charts strong Q3 results bolstered by Novartis Animal Health addition. Item

> After downsizing and delaying IPO, Oasmia pulls off Nasdaq debut. Story

> New app offers remote veterinary visits for pet owners. Article

> Parnell shares advance on strong Q3 revenue growth. Report

Biotech IT News

> Big Pharma follows cash-strapped seniors onto the darknet. Story

> Silicon Valley's thrust into biotech sparks scramble for data scientists. Report

> J&J inks deal to access Nuevolution's informatics-enabled discovery platform. News

> Genentech deal continues big 2015 for in silico specialist Nimbus. Article

> Novartis, Qualcomm joint venture backs $6.5M Series A round for Science 37. More

Pharma Marketing News

> AbbVie faces the music with Express Scripts over FDA's Viekira Pak warning. Item

> J&J's Yondelis finally captures FDA nod, but path to big sales could be steep. More

> The eyes may have it, but pharma still needs convincing on branded visual comms. Report

> Sales reps need to bone up on tech skills as drug launches move digital. Story

> Biogen to put layoffs savings toward DTC, patient support for lagging Tecfidera. Article

Suggested Articles

Outgoing BIO Chair John Maraganore and his successor, Jeremy Levin, reflected on drug pricing, its drivers and its place in the innovation ecosystem.

The study is assessing the effect of the oral AXL inhibitor when given to elderly AML patients in combination with low-intensity chemotherapy.

The proportion of patients who had a greater than 1 g/dL increase in hemoglobin is down on GBT’s prior update but still superior to placebo.